Melanoma Antigen Peptides MELOE-1 and MELOE-2 for Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The identification of additional melanoma antigens with documented immunogenic potential remains a major issue in cancer immunotherapy, particularly for melanoma, as existing antigens like Melan-A/MART-1 have limited understanding of their immunogenicity.
Innovation Solution
The discovery of novel melanoma antigen peptides, MELOE-1 and MELOE-2, which are recognized by T cells and overexpressed in melanoma cells, allowing for the development of specific immunotherapies and diagnostic methods, including expression vectors, host cells, antibodies, and MHC/peptide multimers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing melanoma antigens like Melan-A/MART-1 are used for immunotherapy, then treatment protocols can be established, but the immunogenicity understanding remains limited and additional antigens are needed
Solution Approach 1:
The patent replaces traditional mechanical/purification-based antigen identification methods with a bioinformatics approach. By using computational algorithms to analyze protein sequences and predict T-cell epitopes, the invention systematically identifies novel melanoma antigens (MELOE-1 and MELOE-2) without relying on labor-intensive purification and screening methods, thereby improving reliability while managing complexity
Solution Approach 2:
The invention changes the parameters of antigen identification by focusing on specific sequence motifs and structural features that are predictive of immunogenicity. By analyzing amino acid sequences for specific patterns and using bioinformatics parameters to score potential epitopes, the patent systematically identifies antigens with documented immunogenic potential, resolving the contradiction between reliability and complexity
2Reliability
If multiple melanoma antigens are identified and tested, then immunogenic potential can be evaluated, but the time and resources required for identification increase
Solution Approach 1:
The patent applies preliminary action by using bioinformatics analysis to pre-screen and predict which protein sequences are likely to be immunogenic before experimental validation. By computationally identifying candidate antigens based on sequence features and epitope prediction algorithms, the invention reduces the time and resources needed for subsequent experimental testing, directly addressing the time-loss contradiction
Solution Approach 2:
The invention substitutes time-consuming wet-lab screening methods with computational bioinformatics approaches. By using algorithms to rapidly analyze protein sequences and predict T-cell epitopes, the patent accelerates the identification process while maintaining reliable evaluation of immunogenic potential, thereby reducing identification time without sacrificing reliability
Data Source
AI summary
The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.